Inovio Pharmaceuticals Inc (INO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $267.85M
Last updated: Nov 17, 2026 at 11:06 AM ET
Inovio Pharmaceuticals Inc (INO) Stock Forecast
Analysts expect Inovio Pharmaceuticals (INO) to earn -$0.73 per share in the fiscal year ending Dec 31, 2026. Of 3 analysts, 2 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 67% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 33.3% |
| Buy | 1 | 33.3% |
| Hold | 1 | 33.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$0.73
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.42
- EPS consensus, revenue $64.73M
- Next report
- Mar 10, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.73 | -$0.73 to -$0.73 | 1 | N/A | N/A | 3 |
| Dec 31, 2027 | -$0.42 | -$0.81 to -$0.03 | 2 | $64.73M | $40.00M to $108.00M | 3 |
Quarterly Estimates
The EPS consensus rises from -$0.20 for the quarter ending Dec 31, 2026 to -$0.17 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.20 | -$0.22 to -$0.19 | 4 | $673337 | N/A | 4 |
| Mar 31, 2027 | -$0.17 | -$0.22 to -$0.12 | 2 | $7.00M | $6.00M to $8.00M | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 5 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.14.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.73 | -$1.00 | -$0.73 | -$0.73 | -$1.14 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.42 | -$0.44 | -$0.44 | -$0.44 | -$0.46 | N/A |
| Quarter ending Mar 31, 2027 | -$0.17 | -$0.18 | -$0.18 | -$0.18 | -$0.19 | N/A |
Frequently Asked Questions About INO
What is the INO stock forecast?
Consensus analyst estimates put Inovio Pharmaceuticals's EPS at -$0.73 for the fiscal year ending Dec 31, 2026. The consensus rating from 3 analysts is Buy.
How do analysts rate INO stock?
Of 3 analysts covering Inovio Pharmaceuticals, 1 rates it Strong Buy, 1 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from INO next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.73, with estimates from -$0.73 to -$0.73 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.42, with estimates from -$0.81 to -$0.03 from 2 analysts.
What revenue do analysts expect from Inovio Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $64.73M, with estimates from $40.00M to $108.00M.
How many analysts cover INO?
3 analysts rate Inovio Pharmaceuticals stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
INO pages: Overview, Earnings, Forecast, Financials, Competitors